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Senescence is the irreversible arrest of cell proliferation that has now been shown
to play an important role in both health and disease. With increasing age senescent
cells accumulate throughout the body, including the bone marrow and this has been
associated with a number of age-related pathologies including malignancies. It has
been shown that the senescence associated secretory phenotype (SASP) creates a
pro-tumoural environment that supports proliferation and survival of malignant cells.
Understanding the role of senescent cells in tumor development better may help us to
identify new treatment targets to impair tumor survival and reduce treatment resistance.
In this review, we will specifically discuss the role of senescence in the aging bone
marrow (BM) microenvironment. Many BM disorders are age-related diseases and highly
dependent on the BM microenvironment. Despite advances in drug development the
prognosis particularly for older patients remains poor and new treatment approaches
are needed to improve outcomes for patients. In this review, we will focus on the
relationship of senescence and hematological malignancies, how senescence promotes
cancer development and how malignant cells induce senescence.
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INTRODUCTION
Bonemarrow disorders, includingmyeloproliferative neoplasm (MPN), myelodysplastic syndrome
(MDS), leukemia, and multiple myeloma are largely diseases of the elderly and as our population
ages their incidence will likely continue to increase and with it, disease associated mortality.
Acute myeloid leukemia (AML), alone accounted for 85,000 deaths globally in 2016 and multiple
myeloma caused 98,000 deaths (1). As an example, AML has a peak incidence between the ages of
80 and 85 years (2); its prognosis remains especially poor for many of our older patients who cannot
tolerate the intensive chemotherapies available, with a 5-year survival rate of only 5% in patients
over the age of 65. Even younger patients, who achieve remission, frequently relapse from minimal
residual diseased cells sequestered in the BM. Whilst, the outcomes for patients with multiple
myeloma have improved with new therapies including lenalidomide, bortezomib, autologous stem
cell transplantation and most recently daratumumab, it remains a largely incurable disease and
despite achieving periods of remission most patients will eventually relapse (3). Hematopoietic
malignancies including AML multiple myeloma, MPNs and MDS are highly dependent on the BM
microenvironment for survival (3–7).
The BM is the primary hematopoietic organ in adults. It comprises of blood vessels, nerve tissue
and a heterogeneous population of cells that are either directly involved in the generation of blood
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cells or support the hematopoietic function of the tissue (8,
9). Together, all the components of the BM tightly regulate
normal hematopoiesis to ensure adequate production of mature
blood cells. In blood cancers, however, this process is disrupted
resulting in cytopenias and immunosuppression. In AML, this
is thought to be instigated by leukemic cells directly blocking
differentiation of normal hematopoietic stem cells (HSC) (10),
as well as the manipulation of other BM-derived cells (including
macrophages, endothelial cells, fibroblasts, and adipocytes) (4,
6, 11, 12). The hallmarks of Myeloma include anemia, which
is partly due to bone marrow failure, and lytic bone disease
caused by an imbalance of osteoclast and osteoblast activity,
which is mediated by the malignant plasma cells (13–15).
These are only two examples of how malignant cells alter their
microenvironment to promote tumor survival and proliferation
(4–6, 16). Given the impact tumor cells have on their surrounding
cells, it follows that this interaction between malignant cells
and the BM microenvironment could be utilized to explore
new treatment approaches that are clearly needed for these
lethal diseases.
SENESCENCE
Cellular senescence is the irreversible arrest of cell proliferation
(17). It is associated with the secretion of numerous pro-
inflammatory cytokines, chemokines, proteases, and growth
factors, known as the senescence-associated secretory phenotype
(SASP). It occurs as a response to cellular damage and is thought
to have evolved to both suppress development of cancer and
to promote tissue repair and wound healing (18). In addition
to cellular damage a number of external triggers, including
oxidative stress, radiation, and cytotoxic chemotherapy can cause
DNA damage and as a result induce cellular senescence. It is
mediated by the cyclin-dependent kinase inhibitors p16 and
p21, which mediate cell cycle arrest through the retinoblastoma
and p53 tumor suppressor pathways, respectively (19). In the
short term the SASP plays an important role in recruiting
immune cells to sites of cellular damage in order to promote
tissue repair, limit tissue fibrosis and clear senescent cells.
However, it appears that this process becomes less effective
with age and senescent cells gradually accumulate. Overall the
senescent response becomes maladaptive and there is now
increasing evidence that it contributes to a number of age-related
phenotypes and pathologies. When it persists over time the SASP
has paradoxically been shown to disrupt a number of cellular
and tissue functions to create a pro-tumoral and chemotherapy-
resistant environment (19, 20).
Activation of tumor suppressor pathways prevents cell cycle
progression and can cause either activation of downstream
pathways that eventually result in apoptosis or pathways that
ultimately induce a senescent phenotype. The exact mechanisms
by which the fate of the cell is determined is not yet fully
understood but a number of factors appear to contribute.
These includes the type of cell, the degree of stress which
for example includes the dose of chemotherapy and the
balance of pro-senescent and pro-apoptotic signals which are
at least partly determined by the cell’s microenvironment
(21–23). It appears that once the cell commits to the
senescent phenotype it is protected from pro-apoptotic
stimuli (24).
A number of different models to study senescence in vivo
now exist. These include models that allow identification of
senescent cells ex vivo using fluorescent tags (25), detection of
senescent populations in vivo (26, 27), and selective elimination
of senescent cells (25). In the p16-3MR model, developed by the
Campisi group, these are all combined and the p16 promotor
drives expression of renilla luciferase, red fluorescent protein
(RFP) and HSV thymidine kinase. This allows in vivo imaging
of senescent cells using luminescence, isolation of senescent cells
in vitro and selective depletion of senescent cells using the pro-
drug ganciclovir (18). The limitation of the p16-3MR model is
the low signal of both the renilla luciferase and the RFP. It is not
possible to detect the renilla signal within deep tissues or the bone
marrow in vivo. Moreover, the p16 driven RFP signal is weak and
therefore difficult to detect ex vivo. To address this, the Sharpless
group developed a model using the ultrabright fluorochrome
tandem dimer Tomato (p16-tdTom), which allows for better
analysis and isolation of senescent cells (28). However, unlike the
p16-3MR model, this model has no way of depleting senescent
cells, an aspect that is important to consider when studying the
role of senescence in aging and age-related diseases. Thus, the
ideal model to study senescence in vivo would incorporate the
brightness of the p16-tdTom with the depletion aspect of the
p16-3MR model.
SENESCENCE IN THE AGING BONE
MARROW
The bone marrow is the primary site of hematopoiesis in
adults. HSCs proliferate and differentiate to produce mature
myeloid, lymphoid and erythroid cells and platelets. Supporting
cells, including endothelial cells, fibroblasts, osteoblasts, and
adipocytes help to regulate this process and ensure a balanced
production of mature blood cells. With age the bone marrow
structure changes significantly, as the cellular component is
gradually replaced by adipose tissue (29). The proportion of
highly hematopoietically active red marrow gradually falls and
there as an increase in fatty non-hematopoietic yellow marrow
(30, 31). Furthermore, HSCs from aged mice have altered
gene expression with an upregulation of genes involved in
inflammatory and stress responses (32) as well as reduced
self-renewal and long-term repopulation ability with skewed
differentiation toward the myeloid lineage (33, 34). Thus, whilst
some normal hemtopoiesis continues, with age HSCs gradually
decline in function, resulting in dysregulation of normal
hematopoiesis. This directly alters the BM microenvironment
and likely contributes to the pathogenesis of the many age-
related bone marrow disorders, including AML, chronic myeloid
leukemia, chronic lymphocytic leukemia and myleloma. In
addition, these changes in the HSC pool impact on the
immune system and immunosurveillance, a process known
as immunosenescence (35, 36). This not only affects the
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bone marrow microenvironment but has much broader health
implications for our aging populations as it contributes to other
age-related disease, such as infectious diseases, autoimmune
diseases and solid tumors.
CLONAL HEMATOPOIESIS
Increasing age is associated with an accumulation of mutations
and the nature of the mutation determines the cell’s fate. The
bone marrow is a site of very high cell turnover with trillions
of cells being produced daily through clonal expansion of HSCs
and progenitor cells (37). Mutations may give a selective survival
and proliferative advantage and if they arise within the HSC or
early progenitor cells, they will be passed down to all daughter
cells and as a result are detectable in cells circulating in the
peripheral blood. Clonally expanding cell populations can be
detected in patients with pre-malignant conditions, such as
monoclonal gammopathy of unknown significance (MGUS),
in which an initiating event results in clonal proliferation of
plasma cells but this only progresses to multiple myeloma if
further mutations are acquired (38). Clonal hematopoiesis can
be triggered by skewed X chromosome inactivation as well as
somatic mutations, including most commonly in the DNM3TA,
TET2, and ASXL1 genes (39, 40). These mutations are commonly
associated with myeloproliferative disorders, MDS and AML
but clonal hematopoiesis associated with these mutations has
also been linked to other age-related pathologies including
cardiovascular disease even in the absence of any hematological
disorder (41). The exact mechanism for this remains to be fully
explored but this may be related to altered macrophage function
resulting in impaired immunosurveillance which could lead to
reduced clearance of senescent cells in these tissues. It is possible
that age-related changes within the BM microenvironment,
including accumulation of senescent cells, pro-inflammatory
changes and the secretion of the SASP, favor clonal expansions as
mutated cells adapt to survive and proliferate in the increasingly
adverse environment, whilst normal hematopoiesis is impaired in
these conditions.
CHEMOTHERAPY INDUCED
SENESCENCE
Cytotoxic chemotherapy drugs are used widely in the
management of both solid and hematological malignancies.
AML is a good example in which cytotoxic drugs are frequently
used and senescence is known to contribute to the disease
pathogenesis. Although new drugs are being introduced into
treatment regimens for AML, including targeted treatments,
such as FLT3 inhibitors and immunotherapy agents, the
backbone of AML treatment has been the same for many years
and consists of daunorubicin and cytarabine (42). Daunorubicin
is an anthracycline cytotoxic antibiotic which intercalates with
DNA and inhibits topoisomerase II function, resulting in a
DNA damage response and its cytotoxic effect. Cytarabine is an
antimetabolite which inhibits DNA synthesis and its action is
specific to the S-phase of the cell cycle. Together these cytotoxic
agents alter the cellular state which can, not only lead directly to
cell death but it can also induce a senescent state. This is partly
a desired effect in the treatment of malignancies as it inhibits
the proliferation of malignant cells and can also stimulate
immunosurveillance and therefore clearance of malignant cells
(43, 44). In fact, the method of action of retinoic acid and
arsenic trioxide, the only curative targeted cancer therapy used
in the treatment of acute promyelocytic leukemia, is to induce
senescence in the leukemic cells through activation of the p53
pathway (45) (Figure 1A). Other cytotoxic chemotherapy agents,
however, are non-specific and they can therefore also induce
senescence in healthy tissues (46), thus impacting on the tumor
microenvironment and other healthy organs and tissues. A
number of chemotherapy agents with varying modes of action,
including anthracyclines have been shown induce senescence in
non-cancerous tissue, resulting in the generation of the SASP,
which creates a chronic inflammatory state that is thought to
contribute to the side effects associated with chemotherapy
treatments (20, 47). Furthermore, clearance of senescent cells
within the tumor microenvironment was shown to reduce
recurrence and metastases of solid tumor (46). Thus, in the
tumor microenvironment senescent cells not only affect the
normal function of healthy tissues but they can also promote
tumor survival (Figure 1B).
SENESCENCE IN THE TUMOR
MICROENVIRONMENT
There is increasing evidence that the tumor microenvironment
is crucial for tumor development, survival and drug resistance
(3–7, 16). It should therefore be considered that age related
changes within the BM microenvironment contribute to the
development of hematological malignancies. These changes can
also affect disease progression and response to treatment, and
this may contribute, for example, to poorer outcomes observed
in older patients with AML, which are not sufficiently explained
by the differences in adverse prognostic features (48). AML cells
were shown to induce a senescent phenotype in BM stromal
cells (BMSCs) resulting in the secretion of a SASP which
supports the survival and proliferation of leukemic blasts. In vivo
experiments, using the p16-3MR model of senescence, showed
that leukemic blast derived superoxide induces p16INK4A driven
senescence in BMSCs (CD45-, CD105+, CD140a+, CD31–
and ter119–) and that deletion of these senescent BMSCs
slows tumor progression and prolongs animal survival (49).
As another example multiple myeloma cells have been shown
to induce a SASP (50) and senescence in mesenchymal stem
cells which creates an environment that supports myeloma cells
growth (51, 52), although the exact relationship between the
myeloma cells and the senescent mesenchymal stem cells remains
to be explored further (53). However, as with a number of
solid tumors it is becoming increasingly clear that a senescent
microenvironment favors survival of malignant cells in the
bone marrow. It remains yet to be determined whether an
existing senescent environment, as is observed with increasing
age (Figure 2A), drives the development of these malignancies
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FIGURE 1 | (A,B) The desired and adverse effect of cytotoxic chemotherapy. By inducing senescence in the malignant cell these treatments inhibit cell proliferation
and promote clearance of senescent cells through activation of the immune system. Conversely when a senescent phenotype occurs within the tumor
microenvironment this can promote chronic inflammation, tumor growth and it can impair normal bone marrow function.
or whether in fact the expansion of clonal cell populations within
the bonemarrowmicroenvironment drives the senescent process
(Figure 2B), accelerates aging and impairs immunosurveillance
and clearance of both senescent cells and pre-malignant cells.
It is also possible that these two processes together create the
senescent BM microenvironment that is observed both with
increasing age and in BM malignancies (Figure 2C). However,
as there is increasing evidence that senescence in the bone
marrow microenvironment forms a fundamental part of the
malignant phenotype, this raises the question whether targeting
the “benign” senescent cells in the BM microenvironment could
disrupt the supportive nature of the tumor microenvironment
and as a result impair tumor survival. Thus, providing a potential
new treatment target.
ANTI-SENOLYTICS AS POTENTIAL
THERAPY FOR AML
The p16-3MR mouse model of senescence was used to show that
AML induces senescence in its microenvironment and that this
occurs in the absence of any treatment with chemotherapy (49).
Furthermore, it is known that many of the cytotoxic treatments
used to treat AML can induce senescence in healthy tissues
including the bone marrow microenvironment. Thus, both AML
and its treatment will contribute to a senescent phenotype in
the bone marrow environment. This has been shown to promote
tumor survival but at the same time impair normal hematopoiesis
(19, 35, 46, 49), which may not only contribute to treatment
resistance and relapse of disease but also to immediate and long-
term side effects associated with chemotherapy treatments. It
therefore follows that it would be beneficial to eliminate senescent
cells in the BM microenvironment. A number of senolytic
agents which can selectively eliminate senescent cells have been
identified (24, 54–56). The anti-apoptotic proteins BCL-2 and
BCL-XL have been implicated in protecting senescent cells from
pro-apoptotic signals and a number of inhibitors of the BCL-
2 family have been developed. Of these venetoclax, a selective
BCL-2 inhibitor (57) has been licensed for clinical use and is
currently used in the treatment of chronic lymphocytic leukemia
and AML. It is an example of how targeted treatments can be
effective in treating older patients whilst causing less toxicity than
other existing cytotoxic treatment regimens (58, 59). However,
despite its action as a BCL-2 inhibitor, venetoclax does not have
any significant senolytic activity (24, 54). Navitoclax, on the other
hand, inhibits both BCL-2 as well as BCL-XL and has been shown
to selectively induce apoptosis in senescent cells in the p16-
3MR mouse model, including senescent HSCs with subsequent
recovery of the hematopoietic system (54). However, given the
nature of HSC it could be debated whether it is possible for
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FIGURE 2 | The exact relationship between the senescent phenotype in the BM microenvironment and tumorigenesis remains to be established. We propose three
possible pathways by which the senescent pro-tumoral BM microenvironment is created: (A) The senescent process is driven by normal aging and external factors
and this creates an environment in which clonal hematopoiesis and tumorigenesis is favored. (B) The clonally expanding cell populations are the primary drivers of
senescence in the BM microenvironment. (C) These two processes occur in parallel, impact on each other to varying degrees and together drive the observed
changes in the BM.
them to become senescent, thus, the observed effect could be a
result of depletion of other senescent cells of the bone marrow
microenvironment. Alternatively, high levels of expression of
BCL-XL and BCL-2 may not be unique to senescent cells, and
therefore navitoclax may not be specific to senescent cells in
this context; this could have implications for its clinical use and
would require further investigation. It would be of interest to
further investigate BCL-XL inhibitors in isolation to determine
if BCL-XL inhibition is sufficient to deplete senescent cells or if
simultaneous inhibition of both BCL-2 and BCL-XL is required.
No work has yet shown whether this would be transferrable
to the leukemic microenvironment or other hematological
malignancies, however, if senescent cells can be eliminated from
the tumor microenvironment this may not only affect tumor
survival and chemotherapy resistance but also promote recovery
of normal hematopoiesis and immunosurveillance within the
bone marrow.
CONCLUSION
As our population ages, the burden of age-related diseases will
increase, and new treatment approaches are being explored to
improve heath-span and reduce long-term disease burdens.
For this it is essential to first understand the relationship
between aging and disease. Here we have focused on
bone marrow malignancies, their dependence on the bone
Frontiers in Oncology | www.frontiersin.org 5 February 2020 | Volume 10 | Article 230
Hellmich et al. Senescence in the Leukemic Microenvironment
marrow microenvironment and the role of senescence in their
development, survival and treatment. Senescence is a complex
process involving numerous cellular and molecular pathways
that are influenced by internal and external triggers and whilst
our understanding of these mechanisms is increasing, many
unanswered questions remain. We know that cellular senescence
plays a vital role in wound healing, tumor suppression and
treatment of malignancies but that it also can have a detrimental
effect and contribute to age-related pathologies including
hematological malignancies. There is clearly a fine balance
between the beneficial and detrimental effects of cellular
senescence and understanding this balance will be crucial if we
wish to exploit this process in the treatment of cancer and other
age-related diseases.
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